Advanced Micro Devices delivered its strongest quarter on record in Q2 2026, reporting revenue of $11.54 billion — a 50% increase year over year — yet the stock fell nearly 9% in after-hours trading. For long-term investors who understand how durable competitive advantages compound, that post-earnings selloff may turn out to be the most important data point in the entire report.

The headline number tells only part of the story. AMD’s Data Center segment — which now includes both its EPYC server processors and Instinct AI accelerators — generated $6.72 billion in Q2, up 107% year over year and representing 58% of total company revenue, compared to just 42% a year earlier. Data center operating income reached $2.1 billion, implying a segment operating margin above 31%. CEO Lisa Su guided Q3 revenue to approximately $13 billion and, on the earnings call, stated that AMD expects data center revenue to more than double again in 2027 as Helios rack-scale AI infrastructure systems ramp at volume. Server CPU total addressable market is now projected to exceed $120 billion by 2030, according to AMD’s own modeling — a number that would have seemed absurd three years ago.

The Helios platform is worth watching carefully. Rather than competing with Nvidia only on individual GPU benchmarks, AMD is now shipping an integrated rack-scale solution that bundles EPYC CPUs, Instinct MI450 accelerators, and high-speed networking into a single deployable unit — precisely the kind of system-level architecture that hyperscalers like Microsoft, Google, and Oracle increasingly prefer. AMD’s growing AI partnership roster, combined with the 6th generation EPYC CPU launch, suggests this is not a company fighting for scraps at Nvidia’s table but one methodically building a parallel AI infrastructure stack. Unit sales growth outpaced average selling price growth last quarter, which means volume expansion — not just price inflation — is driving the revenue curve upward.

The stock’s decline after a beat comes down to expectations: AMD had rallied 21% in the five trading sessions leading into earnings, embedding a perfection premium that even a 107% data center growth rate couldn’t satisfy. That dynamic is not a business problem; it is a sentiment problem. For patient long-term investors, the distinction matters enormously. The fundamentals — accelerating data center share, a ramp in rack-scale systems, a server CPU TAM expanding toward nine figures, and operating margins expanding structurally — remain intact and are, if anything, reinforced by Q2’s results. When the market sells off a compounding business because the stock had run too far into earnings, the business does not get cheaper. But the entry point does.

When investors look at Amazon’s Q2 2026 earnings, most fixate on the headline risk: $220 billion in capital expenditures committed for the year, negative free cash flow of $7.6 billion in the quarter, and long-term debt that has climbed to $119 billion. It looks, on the surface, like a company spending recklessly into an uncertain AI future. But the number that reframes the entire story sits in a footnote most analysts walk past — a contracted AWS backlog of $496 billion, growing triple digits year over year. That is not speculative demand. That is revenue already sold.

AWS delivered $42.2 billion in Q2 2026 revenue — up 37% year over year, the fastest growth in 18 quarters — running at a $169 billion annualized pace. More importantly, AWS generated $16.6 billion in operating income at a 39.4% margin, accounting for roughly 61% of Amazon’s total operating income of $27.5 billion (itself up 43% year over year). This is the architecture of a compounding business: a cloud infrastructure division with near-monopoly switching costs, expanding margins at scale, and a $496 billion order book that dwarfs its current annual revenue run rate roughly three times over. The capex Amazon is deploying isn’t a bet — it’s the fulfillment leg of contracts already signed by enterprises and governments that have no practical alternative.

The broader Amazon flywheel reinforces the picture. Advertising, often overlooked, continues to grow at a double-digit clip, leveraging Amazon’s unmatched purchase-intent data. Total net sales crossed $200 billion in a single quarter for the first time. Operating cash flow for the trailing twelve months rose 33% to $161 billion. UBS projects Amazon’s net income could reach $509 billion by 2030, driven by AWS margin expansion and advertising leverage. The $220 billion capex program will weigh on near-term free cash flow — but patient investors who understand that pre-committed infrastructure spending against a $496 billion backlog is categorically different from speculative construction are seeing a company systematically converting AI demand into durable, high-margin annuity revenue. For long-term investors, the story isn’t whether Amazon is spending too much. It’s that the demand already exists at a scale that makes the spending look conservative.

When a $550 billion pharmaceutical company grows revenue 48% in a single quarter, it deserves more than a passing glance from long-term investors. Eli Lilly’s second-quarter 2026 results — posted before the opening bell on August 5 — were not a blip. They were structural proof that the company has built one of the deepest, most durable competitive moats in modern medicine.

The numbers are staggering. Total Q2 revenue came in at $23.0 billion, up 48% year-over-year, handily beating Wall Street’s $20.4 billion estimate. The engine behind that growth: Mounjaro (tirzepatide for diabetes) generated $9.9 billion in the quarter — up 91% from a year ago — while Zepbound (tirzepatide for obesity) added another $4.9 billion. Together, a single molecule is producing nearly $15 billion in quarterly revenue, with global penetration still in early innings. Non-GAAP EPS came in at $8.38, well above the $8.84 consensus. Management responded by raising full-year 2026 revenue guidance to $85–$87 billion, up from the prior $82–$85 billion range.

What long-term investors often miss about Lilly is how this dominance compounds. The GLP-1/GIP drug class is not a fad — it is being embedded into standard care pathways for Type 2 diabetes, obesity, cardiovascular disease, and sleep apnea. Retatrutide, Lilly’s next-generation triple-receptor agonist in late-stage trials, produced weight loss equivalent to bariatric surgery in Phase 2 data. Foundayo (orforglipron), recently FDA-approved as the first oral GLP-1, captured 8,000 prescribers in its first three weeks on market — 80% of whom were treating patients who had never used an incretin drug before. That last point matters enormously: it signals market expansion, not cannibalization. Lilly is not merely defending territory — it is continuously enlarging the battlefield it controls.

The moat here is multi-layered. Intellectual property on tirzepatide runs well into the 2030s. Manufacturing scale — Lilly has committed over $20 billion in U.S. facility expansions since 2023 — creates a structural barrier that would take a competitor nearly a decade to replicate. And physician habit-formation with branded drugs in chronic conditions is notoriously sticky. The switching costs in metabolic medicine are real.

So what does this mean for long-term investors? Lilly is not cheap — shares trade at a significant premium to the broader market. But premium multiples compress over time when the underlying earnings engine is this powerful. A company on track for $85+ billion in annual revenue in 2026, with pipeline visibility to retatrutide and potentially a dozen more assets, is one where the question is not “if” it compounds wealth — it’s “for how long.” Patient investors who focus on earnings power rather than near-term price noise may find that Lilly’s story is only in the middle chapters.

Most investors think of Mastercard as a credit card company. That framing undersells the business by a wide margin — sometimes literally. When Mastercard reported second-quarter 2026 results on July 30, the numbers underneath the headline told a more powerful story: a business running at 61.1% adjusted operating margins, growing profit 19% year-over-year to $4.4 billion, while collecting a quiet tax on virtually every digital dollar that moves across borders.

The quarter’s fundamentals were broad-based and durable. Revenue rose 14% to $9.3 billion, with adjusted earnings per share of $5.04 beating the consensus estimate of $4.77 by 6%. Gross Dollar Volume — the total value of transactions flowing through the Mastercard network — climbed 8% to $2.9 trillion in a single quarter. Switched transactions grew 9% globally, with international markets outside the U.S. expanding at 12%, nearly double the domestic rate. Cross-border volumes, the highest-margin revenue stream in the business, benefited from both a resurgent global travel environment and a World Cup 2026 spending surge that moved billions through the network. Value-added services — fraud prevention, analytics, identity verification, currency conversion — grew 20%, now functioning as a structural layer on top of the core payment rails and commanding premium pricing that pure network fees alone cannot.

What makes Mastercard’s long-term thesis particularly compelling is that the company earns a fraction of a cent on every swipe, tap, or tap-to-pay transaction — and that fraction scales effortlessly. There are no inventory costs, no manufacturing waste, no raw material exposure. As global commerce migrates further toward digital — from in-store NFC payments to e-commerce to cross-border B2B transfers — Mastercard’s two-sided network only becomes harder to displace. The company is now extending that moat into the next era of commerce. CFO Sachin Mehra confirmed that “Agent Pay,” Mastercard’s agentic AI commerce platform, is processing live transactions globally — meaning the same trusted network rails that settled $2.9 trillion in GDV last quarter are now being embedded into AI agent-driven purchases. Stablecoin settlement integration is also underway, ensuring Mastercard captures digital asset flows as that market matures rather than watching from the sidelines.

For long-term investors, the key insight is compounding at scale. Mastercard doesn’t need global GDP to boom — it only needs global commerce to continue digitizing, which has decades of runway remaining. Cash still accounts for roughly 80% of consumer transactions worldwide, particularly in emerging markets where Mastercard’s international volume growth is already running at twice the U.S. rate. Each percentage point of cash-to-digital conversion represents hundreds of billions in new GDV flowing through a network that exists, is trusted, and charges a fee. That combination — 61% operating margins, 19% profit growth, an unmatched global network, and a front-row seat to AI-powered commerce — is a compounding machine that patient investors have historically been rewarded handsomely for holding.

When Warren Buffett handed the reins of Berkshire Hathaway to Greg Abel in January 2026, the investing world held its breath. Would the new CEO sell down the sprawling conglomerate? Fumble the legendary capital allocation machine? Barely six months in, the early answer is a quiet but decisive no — and Abel’s first moves signal something important for long-term shareholders.

The headline number is Berkshire’s $397–$398 billion cash pile, accumulated primarily under Buffett as equity valuations grew stretched. Abel isn’t letting it sit idle. Rather than building a stock portfolio, he is deploying capital into whole-company acquisitions — folding their earnings directly into Berkshire’s operating results. In Q1 2026, his first full quarter as CEO, operating earnings rose 17.7% year-over-year to $11.35 billion. Insurance underwriting profit surged 28.5%, and BNSF Railway delivered a solid recovery. These are the durable, compounding earnings engines Buffett spent 50 years assembling — and they are clearly accelerating under new management.

Abel’s acquisition fingerprints are already visible. He helped close the $9.7 billion OxyChem deal initiated under Buffett, and independently spearheaded the $6.8 billion acquisition of Taylor Morrison, the U.S. homebuilder. His stated preference: buy great businesses at fair prices, fold them into the Berkshire ecosystem, and let their cash flows compound quietly for decades. When he buys a company outright — rather than shares — shareholders benefit from 100% of its operating earnings, not just a percentage stake. At Berkshire’s scale, the math is powerful: a business generating $800 million annually at a 12x acquisition multiple creates compounding value that accrues directly to BRK shareholders with no drag from market volatility.

Berkshire shares have risen to an eight-month high in 2026, roughly in line with the S&P 500’s 9.6% gain year-to-date. But the more interesting story for patient investors is the Q2 2026 earnings report, the first summer report in Berkshire’s history without Buffett as CEO. Analysts and long-term watchers will scrutinize Abel’s capital allocation decisions, the pace of the cash drawdown, and whether insurance underwriting margins hold. Given Q1’s 28.5% surge in insurance underwriting profit, the underlying engine appears healthy.

For long-term investors, the transition at Berkshire deserves more attention than it has received amid the AI earnings frenzy. Abel is not reinventing the playbook — he is executing it with a subtle twist that actually improves the compounding math. Whole-company acquisitions generate more predictable, consolidated earnings than minority stock positions subject to market mark-to-market swings. With nearly $400 billion in dry powder and a management culture that has never chased trends, Berkshire may be one of the few large-caps positioned to compound shareholder value at a steady clip no matter what the market does next.

When Apple reported a record June quarter on July 30 — $109.4 billion in revenue, up 16% year over year, with earnings per share of $2.02 surging 29% — the market responded by sending shares down roughly 6%. The reason: management guided to only 9–11% revenue growth next quarter, citing “very significant” supply constraints on Mac memory and a gross margin step-down to 47–48%. Wall Street, conditioned for perpetual beats, sold first and asked questions later. Long-term investors should pay attention to the part of the story the market is ignoring.

The headline hiding beneath the noise is Apple’s Services segment. At $30.7 billion in quarterly revenue — up 12% year over year — Services now represents 28% of Apple’s total sales and is growing into a structurally higher-margin business every quarter. Apple set all-time records in cloud services and payment services during the quarter, and the company posted a consolidated gross margin of 50.1%, its best in decades. That figure included a roughly two-percentage-point boost from tariff refunds that likely won’t repeat, which is precisely why management guided margins lower for Q4. Strip out the one-time refund and the underlying margin expansion story remains intact. Apple’s gross margin was just 38% five years ago; today it sits above 50%, a transformation driven almost entirely by the Services engine attached to 1.4 billion active devices worldwide.

The leadership dimension adds another layer. Tim Cook closed his final earnings call — after 15 years at the helm — with a brief thank-you to investors and employees. His successor, hardware engineering veteran John Ternus, inherits a balance sheet with tens of billions in annual free cash flow, a buyback program that has retired roughly 40% of shares outstanding over the past decade, and a $0.27 quarterly dividend that has grown steadily since its 2012 reinstatement. For long-term investors, the transition risk is real but manageable: Ternus was Cook’s own choice, Apple’s product pipeline is multi-year in nature, and the installed-base moat deepens with every iPhone upgrade cycle regardless of who chairs the earnings call. The current 6% pullback — triggered by a one-quarter supply hiccup and a CEO handoff — is the kind of short-term noise that patient investors have historically been rewarded for looking through. A business compounding free cash flow at double-digit rates, with half-century gross margins and a Services flywheel that grows with every device sold, rarely trades at a discount for long.

When a company’s contracted future revenue grows 84% in a single year to $678 billion, that isn’t a headline — it’s a balance sheet for the next decade. Microsoft’s fiscal fourth-quarter 2026 results, released July 29, revealed exactly that: a business whose most important number isn’t the one Wall Street spent two days debating, but the locked-in demand backlog that virtually guarantees what comes after it.

The surface numbers were formidable enough. Total revenue hit $90.0 billion for the quarter, up 18% year-over-year, beating analyst estimates across the board. Azure and other cloud services grew 43% in Q4 — well ahead of the company’s own guidance — and crossed a milestone that no cloud business has reached before: $100 billion in annual revenue for fiscal 2026, up 41% from the $75 billion recorded the prior year. Intelligent Cloud as a whole generated $42.4 billion for the quarter. Microsoft’s operating income came in at $36.4 billion for the quarter, and the company returned $10.2 billion to shareholders in just those three months through dividends and share repurchases. For the full fiscal year, capital returned to shareholders totaled over $40 billion. Meanwhile, net income for the quarter received a meaningful boost from gains on Microsoft’s OpenAI and Anthropic investments — underscoring that its AI bets are beginning to compound in ways that even the income statement doesn’t fully capture yet.

The detail that should command the most attention from patient investors, however, is the commercial remaining performance obligations figure: $678 billion. That number represents signed, contracted enterprise deals that haven’t yet flowed through the income statement. It expanded 84% year-over-year, a pace that dwarfs revenue growth itself. To put it plainly: Microsoft’s customers are pre-committing to cloud and AI capacity years in advance, at a rate that suggests Azure’s $100 billion milestone is less a ceiling than a starting line. Management guided Azure growth of approximately 45% in constant currency for the first quarter of fiscal 2027, and guided H1 FY2027 growth to accelerate further — a statement almost no company of this scale has ever been able to make credibly. The price of that ambition is steep: capital expenditures reached nearly $116 billion for all of fiscal 2026, and FY2027 capex is guided between $255 billion and $260 billion. That number would represent the largest single-year infrastructure investment in corporate history. For short-term investors, the free cash flow math is uncomfortable. For long-term investors, it echoes precisely the period from 2010 to 2015 when Amazon was criticized for “burning cash” on AWS infrastructure that subsequently became the most profitable cloud business on earth.

For long-term investors, the case for Microsoft rests on a moat that is deepening faster than at any point in the company’s history. The $678 billion backlog is not speculative demand; it is signed contracts from enterprises that have chosen Azure as their AI infrastructure layer — a decision that is extraordinarily sticky once made. Microsoft’s integrated stack — Office 365, Teams, GitHub Copilot, Azure OpenAI Service, Dynamics, and Power Platform — means that every enterprise workload migration pulls multiple revenue streams behind it. The dividend, while modest at roughly 0.8% yield, has grown uninterrupted for over two decades and is backed by a business generating more than $100 billion in free cash flow annually. The risk is real: $255 to $260 billion in annual capex requires AI monetization to materialize at scale, and any slowdown in enterprise AI adoption would expose the spending cycle. But for investors with a five-to-ten-year horizon, Microsoft has accomplished something rare — it has built a contracted revenue runway that makes its future more legible, not less.

There is a phrase that long-term investors learn to cherish: accelerating revenue on a massive base. Amazon’s second-quarter 2026 earnings, released July 30, delivered exactly that. AWS grew 37% year over year — its fastest quarterly growth in 18 quarters — reaching $42.2 billion in revenue for the quarter alone. Annualized, that is a $169 billion run rate. For context, that single division would rank as a Fortune 100 company if it stood alone. Yet it is growing like a mid-cap startup.

The numbers across Amazon’s full business were equally striking. Total net sales hit $200.6 billion, up 20% year over year, while operating income surged 43% to $27.5 billion. Advertising revenue climbed 26% to nearly $20 billion — a line item that barely existed a decade ago and now rivals the market cap of many S&P 500 members. CEO Andy Jassy disclosed that Amazon’s AI services and custom silicon businesses — powered by its in-house Trainium chips — have each independently crossed a $25 billion annualized revenue run rate, both growing at triple-digit rates. Anthropic and OpenAI have made multi-year, multi-gigawatt Trainium commitments beginning in 2027, suggesting the pipeline is not slowing. Amazon is not just renting cloud compute — it is becoming the infrastructure layer of the AI economy.

Critics will note the risks. Amazon committed $200 billion in capital expenditures for 2026, and free cash flow on a trailing-twelve-month basis swung to an outflow of $7.6 billion as those investments hit the balance sheet. Short-term, the capex burn is real and investors should watch it. Long-term, however, this mirrors the playbook Amazon ran in 2014–2016, when heavy infrastructure investment was dismissed as reckless — and ultimately built the AWS moat that now generates tens of billions in annual operating profit. The pattern is familiar to those who study capital-intensive compounders: pain now, pricing power later.

For long-term investors, the key question is whether AWS’s growth rate is structural or cyclical. The evidence tilts structural. Enterprise cloud penetration globally still sits well below 50% of workloads. AI inference demand is additive to existing cloud spend, not a substitute for it. And Amazon’s integrated stack — compute, storage, databases, AI models, custom silicon, and advertising — creates switching costs that deepen with every workload migrated. The competitive moat here is not just scale; it is ecosystem lock-in across three distinct revenue engines (cloud, ads, retail) that reinforce one another. Patient investors who can tolerate the capex-heavy transition phase are looking at a business compounding at a pace that most single-asset portfolios cannot replicate.

When Procter & Gamble reported its fiscal year 2026 results on July 29th, the market fixated on the wrong number. Shares fell roughly 3% after net revenue of $87.0 billion came in slightly below Wall Street’s consensus estimate. But long-term investors who looked past the top-line miss found something far more instructive: a company that has now raised its dividend for 70 consecutive years, returned more than $15 billion to shareholders in a single fiscal year, and managed to grow core earnings per share to $6.89 — all in what management described as “a very challenging geopolitical and economic environment.”

The revenue miss matters less than the structural story underneath it. P&G’s organic sales grew 1% for the year, with sequential improvement accelerating into the back half of the fiscal year. The company generated robust operating cash flow to fund its $10 billion dividend payout — part of a $15 billion-plus capital return program — while simultaneously absorbing roughly $1 billion in headwinds from higher raw material, energy, and transportation costs. That management guided fiscal 2027 for 1%–3% organic sales growth despite those cost pressures signals the durability of the underlying franchise: 65 brands, sold in more than 180 countries, anchored in daily consumer necessities from Tide to Pampers to Gillette. These aren’t discretionary purchases that evaporate in a downturn. People wash their clothes, brush their teeth, and diaper their children regardless of the economic cycle.

The dividend record deserves more attention than it typically receives. P&G has paid a dividend without interruption for 136 consecutive years — every single year since its incorporation in 1890. It has raised that dividend for 70 straight years, placing it among an elite group of “Dividend Kings” that have hiked payouts through multiple recessions, wars, inflation spikes, and financial crises. An investor who bought P&G shares 20 years ago and reinvested dividends has seen those reinvested payouts compound into a meaningful portion of their total return. That compounding effect is invisible in a single quarterly earnings headline but becomes the dominant driver of wealth over a decade or two.

For long-term investors, the 3% pullback following yesterday’s results may be precisely the kind of entry point P&G rarely offers. At roughly 20 times earnings, the stock isn’t deeply cheap — but for a business with this level of brand moat, cash generation consistency, and 70-year dividend growth streak, paying a modest premium to own a piece of the compounding machine has historically proven worthwhile. The short-term market is reacting to a revenue line; the patient investor is watching a dividend that has been raised through every crisis of the past seven decades — and shows no sign of stopping.

The numbers coming out of Big Tech’s July earnings season look impressive — revenue beats, AI hype at full throttle, and market caps measuring in the trillions. But step back, and a quieter and more instructive story is unfolding in the data. The Magnificent Seven stocks are collectively trading at roughly 11 times sales and 70 times earnings. At the peak of the dot-com bubble in March 2000, the era’s five dominant technology giants — Microsoft, Cisco, Intel, Oracle, and IBM — traded at 11 times sales and 54 times earnings. That comparison is worth sitting with. Today’s AI leaders are more expensively priced than the companies that preceded one of the most brutal 20-year stretches in market history. Investors who bought those dot-com giants at the peak and held through the bust waited until 2020 — a full two decades — to merely break even.

The parallel isn’t meant to predict a crash. Markets can stay irrational longer than most people expect, and the underlying technology this time is genuine. The lesson isn’t “sell everything” — it’s about price. As InvestorPlace analyst Eric Fry pointed out this week, the dot-com leaders were right about the future; they were catastrophically wrong about the valuations investors assigned to that future. The same dynamic may be playing out today. Meta has now guided for $125 billion to $145 billion in capital expenditures for 2026, up from its prior range of $115 billion to $135 billion. Amazon, Alphabet, and Microsoft are spending similarly staggering sums, with an AI researcher at NYU calling it the “greatest capital misallocation in history” — spending at a rate of more than 12 times the Manhattan Project every single year. Meanwhile, the Philadelphia Semiconductor Index (SOX) is down more than 22% in July alone, its sixth-worst month on record, as questions about circular financing and AI demand sustainability catch up with the most crowded trade on Wall Street.

The rotation that follows boom peaks has a reliable historical pattern: the leaders of the previous cycle rarely lead the next one. In the years after the 2000 tech peak, the compounding came from energy, materials, financials, healthcare, and consumer staples — the “boring” sectors that had been starved of capital while everyone chased bandwidth stocks. Today, patient investors might find the same dynamic emerging. Healthcare stocks and financials have quietly outperformed tech in recent weeks, with Morgan Stanley upgrading quality-dividend names in both sectors. The S&P 500’s tech weighting sits near all-time highs even as earnings growth in non-tech sectors begins to accelerate. For long-term investors, the question isn’t whether to abandon growth entirely — it’s whether the valuations being paid for that growth leave any margin of safety. At 70 times earnings, the Mag 7 as a group prices in perfection. History suggests that, for patient capital, the better compounding opportunities are often found precisely where no one is looking: in the “boring” companies with reasonable valuations, durable cash flows, and the advantage of being invisible to the excitement-chasing crowd.